Magnesium aspartate
Star1
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Magnesium aspartate
- DrugBank Accession Number
- DB13359
- Background
Magnesium aspartate is a magnesium salt of aspartic acid that is commonly used as a mineral supplement. It displays high oral bioavailability and water solubiltiy compared to other magnesium salts such as magnesium citrate, magnesium carbonate and magnesium oxide.
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 360.555
Monoisotopic: 360.08666579 - Chemical Formula
- C8H20MgN2O12
- Synonyms
- (+)-magnesium aspartate tetrahydrate
- Aspartic acid, magnesium salt
- Magnesium aspartate
- Magnesium aspartate tetrahydrate
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Arrhythmias cardiac Combination Product in combination with: Potassium aspartate (DB15819), Potassium chloride (DB00761) •••••••••••• •••••••• Used in combination to treat Combined magnesium and potassium deficiency Combination Product in combination with: Potassium aspartate (DB15819) •••••••••••• •••••••• Used in combination to treat Magnesium deficiency Combination Product in combination with: Potassium aspartate (DB15819), Potassium chloride (DB00761) •••••••••••• •••••••• Used in combination to treat Potassium deficiency Combination Product in combination with: Potassium chloride (DB00761), Potassium aspartate (DB15819) •••••••••••• •••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAlendronic acid Magnesium aspartate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Alfacalcidol The serum concentration of Magnesium aspartate can be increased when it is combined with Alfacalcidol. Amiodarone The risk or severity of hypotension can be increased when Magnesium aspartate is combined with Amiodarone. Amlodipine The risk or severity of hypotension can be increased when Magnesium aspartate is combined with Amlodipine. Atracurium The therapeutic efficacy of Atracurium can be increased when used in combination with Magnesium aspartate. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Dermamed Nutrition for troubled skin Magnesium aspartate (50 mg/1.5g) + Ascorbic acid (30 mg/1.5g) + Copper Cu-64 (1 mg/1.5g) + Thiamine chloride (20 mg/1.5g) + Vitamin A (150 [iU]/1.5g) + Vitamin D (150 [iU]/1.5g) + Zinc gluconate (10 mg/1.5g) Capsule, gelatin coated Oral DermaMed 2019-09-18 Not applicable US Elozell "forte" - Infusionsflasche Magnesium aspartate (2.163 g/250ml) + Potassium aspartate (2.163 g/250ml) Solution Intravenous Fresenius Kabi Austria Gmb H 1970-12-09 Not applicable Austria Elozell "spezial" - Infusionsflasche Magnesium aspartate (2.163 g/250ml) + Potassium aspartate (1.441 g/250ml) + Potassium chloride (1.193 g/250ml) Solution Intravenous Fresenius Kabi Austria Gmb H 1983-01-20 Not applicable Austria FATIGON TABLET Magnesium aspartate (100 mg) + Cyanocobalamin (100 mcg) + Potassium aspartate (100 mg) + Pyridoxine hydrochloride (50 mg) + Thiamine hydrochloride (100 mg) + Vitamin E (30 IU) Tablet Oral THE ZYFAS MEDICAL CO., 2020-09-08 Not applicable Malaysia RENAPAR Magnesium aspartate (100 mg) + Potassium aspartate (300 mg) Tablet, film coated Oral Pratapa Nirmala 2017-02-27 2027-02-27 Indonesia
Categories
- ATC Codes
- A12CC05 — Magnesium aspartate
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- R17X820ROL
- CAS number
- 7018-07-7
- InChI Key
- CRSJYWPXKKSOCQ-CBAPHJFVSA-L
- InChI
- InChI=1S/2C4H7NO4.Mg.4H2O/c2*5-2(4(8)9)1-3(6)7;;;;;/h2*2H,1,5H2,(H,6,7)(H,8,9);;4*1H2/q;;+2;;;;/p-2/t2*2-;;;;;/m00...../s1
- IUPAC Name
- magnesium(2+) bis((2S)-2-amino-3-carboxypropanoate) tetrahydrate
- SMILES
- O.O.O.O.[Mg++].N[C@@H](CC(O)=O)C([O-])=O.N[C@@H](CC(O)=O)C([O-])=O
References
- General References
- TITCK Product Information: Tromcardin (potassium aspartate/magnesium aspartate) solution for injection [Link]
- External Links
- PubChem Substance
- 347911448
- ChemSpider
- 34993538
- 142131
- Wikipedia
- Magnesium_aspartate
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule, gelatin coated Oral Solution Intravenous Tablet Oral Capsule 45 mg Tablet, film coated Oral Injection, solution Intravenous - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 2.98 mg/mL ALOGPS logP -3.8 ALOGPS logP -3.5 Chemaxon logS -2 ALOGPS pKa (Strongest Acidic) 1.7 Chemaxon pKa (Strongest Basic) 9.61 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 103.45 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 37.37 m3·mol-1 Chemaxon Polarizability 10.99 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at June 23, 2017 20:40 / Updated at November 03, 2020 01:20